Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | -35K | -19K |
| Operating Income | -664K | -1M | -2M | -609K | -724K |
| EBITDA | -664K | 0 | -6M | -122K | -705K |
| Net Income | -1M | 3M | -6M | -934K | -12K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 243 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rebus Holdings, Inc. (RBSH) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -109.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -109.2%, free cash flow -1.9% with operating margin 0.0% and ROIC 13.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RBSH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RBSH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RBSH Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RBSH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$12.0K
+98.7% YoY
Free Cash Flow
-$204.0K
+34.8% YoY
Revenue Growth
+0.0%
EPS Growth
-109.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | -35K | -19K |
| Operating Income | -664K | -1M | -2M | -609K | -724K |
| EBITDA | -664K | 0 | -6M | -122K | -705K |
| Net Income | -1M | 3M | -6M | -934K | -12K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5K | 711K | 404K | 4K | 4K |
| Total Assets | 5K | 715K | 404K | 23K | 366K |
| Total Liabilities | 5M | 6M | 13M | 9M | 9M |
| Shareholder Equity | -5M | -5M | -13M | -9M | -8M |
| Total Debt | 310K | 514K | 2M | 3M | 3M |
| Net Debt | 305K | -197K | 1M | 3M | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
204K
+34.8% YoY
Capital Expenditures
0
Free Cash Flow
204K
+34.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
19.9%
Debt / Equity
-0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.